Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01405456 · ClinicalTrials.gov registry record · NA
Eplerenone in HIV Associated Abdominal Fat Accumulation
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 46
- Enrollment target
NCT01405456: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01405456 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01405456, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effects of a drug, eplerenone, along with lifestyle modification to affect sugar metabolism, body fat distribution, and cardiovascular health in HIV-infected individuals. In non-HIV-infected individuals, recent data has shown that aldosterone, a hormone that regulates salt and water balance, is increased in association with increased belly fat and decreased insulin sensitivity. In HIV-infected individuals, aldosterone appears to be higher in individuals with increased belly fat, and increased aldosterone appears to be strongly associated with impaired sugar metabolism. In this study, the investigators will test the effects of eplerenone, which is a medication that blocks the actions of aldosterone, along with lifestyle modification. The investigators hypothesize that eplerenone may improve sugar metabolism, improve markers of cardiovascular health, and reduce fat accumulation in liver and muscle.
Interventions
- DRUG Eplerenone and lifestyle
- OTHER placebo and lifestyle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2012-01 |
| Est. Completion | 2017-11-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01405456
The ClinicalTrials.gov registry entry for NCT01405456 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Eplerenone and lifestyle is the first listed.
NCT01405456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01405456 about?
NCT01405456 is a clinical study titled "Eplerenone in HIV Associated Abdominal Fat Accumulation". The purpose of this study is to test the effects of a drug, eplerenone, along with lifestyle modification to affect sugar metabolism, body fat distribution, and cardiovascular health in HIV-infected individuals. In non-HIV-infected individuals, recent data has shown that aldosterone, a hormone that ...
What is the current status of trial NCT01405456?
This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 2012-01. Estimated completion is 2017-11-01.
What interventions are being tested in trial NCT01405456?
The interventions under investigation include: Eplerenone and lifestyle (DRUG), placebo and lifestyle (OTHER).
Who is sponsoring clinical trial NCT01405456?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.